S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

LeMaitre Vascular (LMAT) Stock Forecast, Price & News

+1.27 (+2.92%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
93,024 shs
Average Volume
180,850 shs
Market Capitalization
$983.36 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive LMAT News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

LeMaitre Vascular logo

About LeMaitre Vascular

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.


Lemaitre Vascular Misses Q1 EPS by 1c
LeMaitre Q1 2022 Financial Results
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$154.42 million
Cash Flow
$1.79 per share
Book Value
$11.74 per share


Net Income
$26.91 million
Pretax Margin




Free Float
Market Cap
$983.36 million

Company Calendar

Ex-Dividend for 3/24 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 6/2 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

3.38 out of 5 stars

Medical Sector

2nd out of 1,416 stocks

Surgical & Medical Instruments Industry

1st out of 138 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 4.2Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -

LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions

Is LeMaitre Vascular a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LeMaitre Vascular stock.
View analyst ratings for LeMaitre Vascular
or view top-rated stocks.

When is LeMaitre Vascular's next earnings date?

LeMaitre Vascular is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for LeMaitre Vascular

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) issued its quarterly earnings data on Thursday, April, 28th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by $0.01. The medical instruments supplier had revenue of $39.56 million for the quarter, compared to analyst estimates of $38.65 million. LeMaitre Vascular had a net margin of 17.09% and a trailing twelve-month return on equity of 11.41%. The firm's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.28 EPS.
View LeMaitre Vascular's earnings history

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Tuesday, April 26th. Stockholders of record on Tuesday, May 17th will be given a dividend of $0.125 per share on Thursday, June 2nd. This represents a $0.50 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date of this dividend is Monday, May 16th.
View LeMaitre Vascular's dividend history

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular pays an annual dividend of $0.50 per share and currently has a dividend yield of 1.15%. LeMaitre Vascular has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of LeMaitre Vascular is 40.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 35.46% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.
View LeMaitre Vascular's dividend history.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular updated its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $0.29-$0.35 for the period, compared to the consensus EPS estimate of $0.39. The company issued revenue guidance of $40.10 million-$42.10 million, compared to the consensus revenue estimate of $42.61 million.

What price target have analysts set for LMAT?

3 equities research analysts have issued twelve-month target prices for LeMaitre Vascular's shares. Their forecasts range from $50.00 to $70.00. On average, they anticipate LeMaitre Vascular's stock price to reach $59.33 in the next twelve months. This suggests a possible upside of 32.4% from the stock's current price.
View analysts' price targets for LeMaitre Vascular
or view top-rated stocks among Wall Street analysts.

Who are LeMaitre Vascular's key executives?
LeMaitre Vascular's management team includes the following people:
What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular CEO George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among LeMaitre Vascular's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include (CGC), AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.47%), Conestoga Capital Advisors LLC (8.56%), Vanguard Group Inc. (6.50%), Copeland Capital Management LLC (5.54%), Geneva Capital Management LLC (3.95%) and State Street Corp (3.23%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends for LeMaitre Vascular

Which major investors are selling LeMaitre Vascular stock?

LMAT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, JPMorgan Chase & Co., Rice Hall James & Associates LLC, Aviva PLC, Geneva Capital Management LLC, Prudential Financial Inc., Principal Financial Group Inc., and Russell Investments Group Ltd.. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, John A Roush, Joseph P Pellegrino Jr, and Trent G Kamke.
View insider buying and selling activity for LeMaitre Vascular
or view top insider-selling stocks.

Which major investors are buying LeMaitre Vascular stock?

LMAT stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Conestoga Capital Advisors LLC, Dimensional Fund Advisors LP, Grandeur Peak Global Advisors LLC, Copeland Capital Management LLC, Royce & Associates LP, and ProShare Advisors LLC.
View insider buying and selling activity for LeMaitre Vascular
or or view top insider-buying stocks.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $44.80.

How much money does LeMaitre Vascular make?

LeMaitre Vascular has a market capitalization of $983.36 million and generates $154.42 million in revenue each year. The medical instruments supplier earns $26.91 million in net income (profit) each year or $1.25 on an earnings per share basis.

How many employees does LeMaitre Vascular have?

LeMaitre Vascular employs 450 workers across the globe.

Does LeMaitre Vascular have any subsidiaries?

The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.

When was LeMaitre Vascular founded?

LeMaitre Vascular was founded in 1983.

What is LeMaitre Vascular's official website?

The official website for LeMaitre Vascular is www.lemaitre.com.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at (781) 221-2266 or via fax at 781-425-5049.

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.